Group items tagged

Raise Awareness of Pancreatic Cancer with custom silicone bracelets and show your support to the person and raise fund.

Did you know that pancreatic cancer has the least survival rates of all cancers? check out everything you need to know about the disease

Steve Jobs has battled a rare form of pancreatic cancer for years, undergoing a series of aggressive treatments, including a liver transplant, and surviving longer than many others with the disease.

Know the Symptoms and Treatments for Pancreatic Cancer and raise awareness with custom made rubber bracelets.

Best Gastroenterology Hospital in India Apollo Hospitals offer expert care in Medical Surgical Gastroenterology and focuses on treatment of digestive tract, liver pancreatic diseases

MedsDelta provides Sunitinib Capsules by Pfizer makes under trade name Sutent capsules, availing at a reasonable price. Sunitinib is for treating a specific sort of stomach, gut, or throat tumor in specific patients. It is additionally used to treat certain sorts of kidney or pancreatic tumor. #MedsDelta exporting Generic Sunitinib Capsules across all over the world, countries like U.K., U.S, Nepal, Philippines, China, Japan, Singapore, Romania, Vietnam, Canada, Hongkong, Russia, and over 150 countries. We at MedsDelta, supplying Generic #Sunitinib Medicines at reasonable prices and giving you accurate information about the product. If you want to order Generic Sunitinib Capsules - #Sutent25mg Capsules, you can contact us anytime 24*7 at -> +91-9971646666, QQ: 3451266709, Skype: medsdelta, WeChat: medsdelta, or mail: medsdelta@gmail.com. We ensure to provide our best services and authentic medication.

A 58-year-old nurse from North Lanarkshire, Scotland, has reportedly died after taking the weight-loss drug tirzepatide, which was recently approved for use on the NHS. Susan McGowan died from multiple organ failure, septic shock and pancreatitis, with the use of the Eli Lilly drug listed as a contributing factor on her death certificate, according to the BBC. She had taken two low-dose injections of tirzepatide, known by the brand name Mounjaro, over a two-week period before her death on 4 September. Her death is thought to be the first in the U.K. officially linked to the drug. McGowan, who had worked for over 30 years as a nurse at University Hospital Monklands in Airdrie, purchased a prescription for the drug through a registered online pharmacy. A few days after her second injection, McGowen began experiencing severe stomach pains and sickness. She went to A&E at Monklands - where her colleagues tried to save her life. Within days, her kidneys failed, and she fell into a coma as her other organs began to fail.

A comprehensive cohort study has shed light on the benefits and risks associated with weight-loss drugs, offering valuable insights for clinical care and future research. Published in Nature Medicine on 20 January 2024, the study found the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs)-used to treat diabetes and obesity-associated with a reduced risk of substance use disorders (including alcohol, cannabis, opioid and stimulant use disorders). Weight-loss drug use was also linked to decreased risks of psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. However, the use of GLP-1RAs was not without risks, as researchers identified an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic conditions, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis associated with their use. The analysis, utilising the U.S. Department of Veterans Affairs databases, compared 215,970 GLP-1 RA users with patients using sulphonylureas (n=159,465), DPP4 inhibitors (n=117,989), SGLT2 inhibitors (n=258,614), or a composite of the three (n=536,068).

Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors

In recent years, Mounjaro, a medication used for managing Type 2 diabetes, has gained significant attention due to its effectiveness in controlling blood sugar levels. However, as with any medication, Mounjaro is not without its side effects. Understanding the potential side effects of Mounjaro is crucial for patients and healthcare providers alike to make informed decisions about its use. Overview of Mounjaro (tirzepatide) Mounjaro, known by its generic name as tirzepatide, is a once-weekly injectable medication developed to help manage blood glucose levels in individuals with Type 2 diabetes. It functions by mimicking the action of the hormone GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which play key roles in regulating insulin secretion and blood sugar levels. Since its introduction, Mounjaro has been praised for its dual-action mechanism that not only helps lower blood sugar levels but also supports weight loss, which is often beneficial for individuals with Type 2 diabetes.